GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
106 hedge funds and large institutions have $368M invested in GenMark Diagnostics, Inc in 2019 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 41 increasing their positions, 28 reducing their positions, and 11 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 28
42% more capital invested
Capital invested by funds: $259M → $368M (+$110M)
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
3% more funds holding
Funds holding: 103 → 106 (+3)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $74K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.76M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$2.33M |
| 3 |
Goldman Sachs
New York
|
+$1.88M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.66M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$9.69M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.93M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.39M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.98M |
| 5 |
CC
Casdin Capital
New York
|
-$2.96M |
GNMK Hedge Fund Activity: Q1 2019 in Review
106 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q1 2019, worth a combined $368M — up 42% from $259M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new GNMK positions and 11 closed out — a net gain of 3 holders — while 41 added to existing stakes and 28 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.76M. The largest seller was JP Morgan Chase, cutting an estimated $9.69M.
- 106 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q1 2019, up from 103 in Q4 2018.
- Funds reported $368M of GenMark Diagnostics, Inc stock for Q1 2019, up 42% quarter-over-quarter.
- 14 funds opened new GenMark Diagnostics, Inc positions in Q1 2019 and 11 closed out, a net change of +3 holders.
- The largest GenMark Diagnostics, Inc buyer in Q1 2019 was Millennium Management, an estimated $2.76M added.
- The largest GenMark Diagnostics, Inc seller in Q1 2019 was JP Morgan Chase, an estimated $9.69M sold.
Based on aggregated 13F filings for Q1 2019.